Sumanta Pal
苏曼塔·帕尔
MD
Clinical Professor and Co-Director, Kidney Cancer Program临床教授兼肾癌项目联合主任
👥Biography 个人简介
Sumanta Pal is a leading kidney cancer expert at City of Hope, known for advancing cabozantinib combinations and IO-based regimens in renal cell carcinoma. He has led multiple international trials improving outcomes for metastatic RCC patients and authored foundational treatment guidelines.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Cabozantinib in Renal Cell Carcinoma
Led studies establishing cabozantinib as a preferred second-line therapy for metastatic RCC, demonstrating superior PFS versus everolimus in the METEOR trial analysis.
Genomic Profiling in RCC
Conducted landmark genomic studies identifying actionable mutations in metastatic RCC, connecting molecular subtypes to treatment selection and informing precision oncology approaches.
Representative Works 代表性著作
Cabozantinib versus Everolimus in Advanced Renal Cell Carcinoma
New England Journal of Medicine (2015)
METEOR trial establishing cabozantinib superiority over everolimus in previously treated metastatic RCC.
Genomic Determinants of Outcomes in Metastatic Clear Cell Renal Cell Carcinoma
European Urology (2020)
Identified genomic alterations predicting response to VEGF-targeted and immunotherapy regimens in mRCC.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Brian I. Rini
Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
Robert J. Motzer
Memorial Sloan Kettering Cancer Center
Toni K. Choueiri
Dana-Farber Cancer Institute, Harvard Medical School
Jonathan Rosenberg
Memorial Sloan Kettering Cancer Center
关注 苏曼塔·帕尔 的研究动态
Follow Sumanta Pal's research updates
留下邮箱，当我们发布与 Sumanta Pal（City of Hope Comprehensive Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment